<DOC>
	<DOCNO>NCT01334229</DOCNO>
	<brief_summary>Sitagliptin potent selective inhibitor dipeptidyl peptidase IV ( DPP-IV ) , show reduce fast postprandial glucose level patient type 2 diabetes mainly incretin hormone-mediated improvement islet function [ 13 ] . Although clinical study date indicate fast lipid level minimally affect DPP-IV inhibitor treatment [ 14-16 ] , animal study suggest DPP-IV inhibition reduce intestinal triglyceride ( TG ) absorption apolipoprotein ( apo ) production [ 17 ] increase chylomicron catabolism [ 18 ] . Interestingly , recent study support hypothesis show vildagliptin therapy able reduce postprandial intestinal triglyceride-rich lipoprotein ( TRL ) particles patient type 2 diabetes [ 19 ] . Recently , group report sitagliptin treatment significantly reduce plasma apo B-48 TG concentration postprandial state . Moreover , animal study show sitagliptin decrease intestinal secretion intestinal apo B-48 , mainly increase level glucagon-like peptide ( GLP ) -1 [ 20 ] . Therefore , present study design examine effect sitagliptin kinetics TRL apo B-48 patient type 2 diabetes . A possible reduction postprandial atherogenic TRL apo B-48-containing lipoprotein level sitagliptin would add therapeutic utility DPP-4 inhibitor suggest potential reduce cardiovascular risk patient type 2 diabetes .</brief_summary>
	<brief_title>Sitagliptin Kinetics Triglyceride-rich Lipoproteins Apolipoprotein B48 B100 Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Males 18 65 year age . Postmenopausal woman age 65 stable medical therapy 6 month study ( patient demonstrate stable lipid panel ) Women hormone replacement therapy ( recent start stop ) Type 2 diabetes define American Diabetes Association . Nonsmoker . Body mass index 25.0 40.0 kg/m2 . Baseline glycated hemoglobin A1c ( HbA1c ) 6.5 8.5 % . Baseline fast plasma glucose &lt; 15.0 mmol/L . Plasma triglyceride level 1.5 8.0 mmol/L ( 135 710 mg/dl ) screen week 4 . Patients receive stable dos metformin least 3 month randomization . Subjects must willing give write informed consent able adhere dose schedule , visit schedule phone followup assessment . Patients otherwise generally healthy , without elevation hepatic transaminase abnormal renal function coagulation . Patients normal thyroid stimulate hormone screen Patients extreme dyslipidemias , familial hypercholesterolemia exclude . Patients type 1 diabetes , secondary form diabetes acute metabolic diabetic complication exclude . Patients receive treated insulin thiazolidinedione within past 6 month exclude . Patients take hypoglycemic agent , metformin . Subjects exclude cardiovascular disease ( coronary heart disease , cerebrovascular disease peripheral arterial disease ) take medication know affect lipoprotein metabolism ( e.g . steroid , beta blocker , thiazide diuretic , lipid lower agent , significant alcohol intake etc. ) . Subjects situation condition , opinion investigator , may interfere optimal participation study . Individuals history mental instability , drug alcohol abuse individual treat treat severe psychiatric illness , opinion investigator , may interfere optimal participation study . History alcohol drug abuse within past 2 year . Patients must take alcohol study . Disorders hematologic , digestive , central nervous system , include cerebrovascular disease degenerative disease , would limit study evaluation participation . Known impairment renal function ( serum creatinine level &gt; 1.7 mg/dL men ) , dysproteinemia , nephrotic syndrome , renal disease ( 24hour urinary protein ≥3 ± 1 g ) . Active chronic hepatobiliary hepatic disease . In addition , patient aspartate aminotransferase alanine aminotransferase &gt; 2 x upper limit laboratory reference range exclude . Subjects coagulopathy ( prothrombin time partial thromboplastin time Visit 1 &gt; 1.5 time control ) . Subjects hemoglobin &gt; 2 x low limit laboratory reference range exclude . Patients know tested positive human immunodeficiency virus ( HIV ) . Patients currently enrol another clinical study . Patients used investigational drug within 30 day first clinic visit . Congestive heart failure New York Heart Association ( NYHA ) Class III IV . Uncontrolled cardiac arrhythmia within 3 month study entry . Uncontrolled diabetes mellitus ( HbA1c &gt; 8.5 % ) endocrine metabolic disease know influence serum lipid lipoprotein . Clinically euthyroid subject replacement dose thyroid hormone eligible enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>sitagliptin</keyword>
	<keyword>diabetes</keyword>
	<keyword>apolipoprotein B48 B100</keyword>
</DOC>